https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-august-31-2026/ 2026-09-01T13:06:01Z Pharminent en Rare Disease & Gene Therapy Digest • August 31, 2026 2026-09-01T13:05:58Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-august-28-2026/ 2026-08-31T23:31:15Z Pharminent en Oncology Intelligence Digest • August 28, 2026 2026-08-31T23:31:13Z Blog https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-august-28-2026/ 2026-08-31T23:29:12Z Pharminent en GLP-1 Competitive Market Digest • Weekly • August 28, 2026 2026-08-31T23:29:10Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-august-28-2026/ 2026-08-31T23:25:18Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • August 28, 2026 2026-08-31T23:25:16Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-august-29-2026/ 2026-08-31T23:23:05Z Pharminent en Week in Review • INTELLIGENCE BRIEF • August 29, 2026 2026-08-31T23:23:01Z Blog https://pharminent.com/market-access/market-access-quarterly-deep-dive-q3-2026-pbm-exclusions/ 2026-08-31T23:20:05Z Pharminent en Market Access Quarterly Deep Dive Q3 2026 PBM Exclusions 2026-08-31T23:20:03Z Blog https://pharminent.com/lilly-pays-up-to-2-875-billion-for-merida-and-a-phase-1-autoantibody-platform/ 2026-08-31T19:35:48Z Pharminent en Lilly Pays Up to $2.875 Billion for Merida and a Phase 1 Autoantibody Platform 2026-08-31T19:31:02Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-31-2026/ 2026-08-31T18:46:07Z Pharminent en Strategic News Watch • August 31, 2026 2026-08-31T18:46:05Z Blog https://pharminent.com/lilly-adds-to-immune-drug-pipeline-with-2-9b-merida-buyout/ 2026-09-01T15:24:45Z Pharminent en Lilly adds to immune drug pipeline with $2.9B Merida buyout 2026-08-31T15:23:00Z Blog https://pharminent.com/fda-clears-takeda-protagonists-first-in-class-pv-drug/ 2026-09-01T15:21:00Z Pharminent en FDA clears Takeda, Protagonist's first-in-class PV drug 2026-08-31T14:04:28Z Blog https://pharminent.com/esc-2026-evolocumab-explores-new-frontiers-in-cv-disease-prevention/ 2026-09-01T13:29:20Z Pharminent en ESC 2026: Evolocumab explores new frontiers in CV disease prevention 2026-08-31T13:17:14Z Blog https://pharminent.com/acquisitive-lilly-offers-2-88bn-for-merida-bio/ 2026-09-01T13:29:55Z Pharminent en Acquisitive Lilly offers $2.88bn for Merida Bio 2026-08-31T11:59:24Z Blog